Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhuhai Trinomab Pharmaceutical Co PS Ratio?
Zhuhai Trinomab Pharmaceutical CoSHSE:688806 -4.38%2 PS Ratio is 155.79 as of Sep. 10, 2026, which is 19% below its 10-year median of 192.18. GuruFocus rates SHSE:688806 with a GF Score™ of 2/100. The stock has 7 warning signs investors should review. Among 953 Drug Manufacturers companies, Zhuhai Trinomab Pharmaceutical Co ranks worse than 98.53% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zhuhai Trinomab Pharmaceutical Co's share price is ¥20.72.
Zhuhai Trinomab Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.13. Hence, Zhuhai Trinomab Pharmaceutical Co's PS Ratio for today is 155.79.
During the past 4 years, Zhuhai Trinomab Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 70.10% per year. The lowest was 70.10% per year. And the median was 70.10% per year.
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zhuhai Trinomab Pharmaceutical Co PS Ratio Related Terms
Zhuhai Trinomab Pharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhuhai Trinomab Pharmaceutical Co PS Ratio Chart
Zhuhai Trinomab Pharmaceutical Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
0.00
Zhuhai Trinomab Pharmaceutical Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
0.00
SHSE:688806 vs ZTS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhuhai Trinomab Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhuhai Trinomab Pharmaceutical Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhuhai Trinomab Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zhuhai Trinomab Pharmaceutical Co's PS Ratio falls into.
Zhuhai Trinomab Pharmaceutical Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zhuhai Trinomab Pharmaceutical Co's Share Price of today is ¥20.72.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Zhuhai Trinomab Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a PS Ratio of 155.79 as of Sep. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors. This is 19% below median its historical median of 192.18. Over the past decade, Zhuhai Trinomab Pharmaceutical Co's PS Ratio has ranged from 155.79 to 211.95. According to the industry distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #939 out of 953 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is Zhuhai Trinomab Pharmaceutical Co's PS Ratio too high?
Zhuhai Trinomab Pharmaceutical Co's current PS Ratio of 155.79 is 19% below median its 10-year median of 192.18. Over the past 10 years, this metric has ranged from a low of 155.79 to a high of 211.95. The Drug Manufacturers industry median PS Ratio is 2.32. Zhuhai Trinomab Pharmaceutical Co's value of 155.79 is 6615.1% above this industry median. Based on the distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #939 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhuhai Trinomab Pharmaceutical Co has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Zhuhai Trinomab Pharmaceutical Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #939 out of 953 companies for PS Ratio. This places Zhuhai Trinomab Pharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 2.32. Zhuhai Trinomab Pharmaceutical Co's value of 155.79 is 6615.1% above this benchmark. Historically, Zhuhai Trinomab Pharmaceutical Co's own PS Ratio has ranged from 155.79 to 211.95 over the past decade. While the company's 10-year median is 192.18 vs. the industry median of 2.32, Zhuhai Trinomab Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhuhai Trinomab Pharmaceutical Co's current PS Ratio of 155.79 is 6615.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhuhai Trinomab Pharmaceutical Co's current PS Ratio is 155.79, which is 19% below median its own 10-year median of 192.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhuhai Trinomab Pharmaceutical Co stock overvalued right now?
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a current PS Ratio of 155.79. The current PS Ratio is 155.79, which is 19% below median its 10-year median of 192.18 and 6615.1% above the Drug Manufacturers industry median of 2.32. Zhuhai Trinomab Pharmaceutical Co's overall GF Score™ is 2/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zhuhai Trinomab Pharmaceutical Co (SHSE:688806), the current PS Ratio is 155.79 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688806 has been successfully added to your 
